Literature DB >> 17928752

[Comparison of CTP, MELD, and MELD-Na scores for predicting short term mortality in patients with liver cirrhosis].

Se Yune Kim1, Hyung Joon Yim, Juneyoung Lee, Beom Jae Lee, Dong Il Kim, Sung Woo Jung, Woo Sik Han, Jong Sup Lee, Ja Seol Koo, Yeon Seok Seo, Jong Eun Yeon, Hong Sik Lee, Sang Woo Lee, Soon Ho Um, Kwan Soo Byun, Jai Hyun Choi, Ho Sang Ryu.   

Abstract

BACKGROUND/AIMS: MELD-Na (model for end-stage liver disease with incorporation of serum sodium) was suggested to provide better survival prediction than MELD alone for patients with end stage liver disease. However, there is no data verifying the usefulness of MELD-Na for predicting short term mortality of cirrhotic patients in Korea. This study was aimed to determine whether MELD-Na would be more accurate in predicting short term mortality than other scoring systems such as Child-Turcotte-Pugh (CTP) or MELD.
METHODS: Data from 355 patients admitted due to liver cirrhosis were retrospectively reviewed. The cumulative survival rates were obtained. Prediction of mortality rate for three months and one year were analyzed using the area under the receiver's operating characteristics curve (AUC).
RESULTS: One hundred patients (28%) died during the study period. All of the three systems showed significant differences in the cumulative survival rate according to the scores on admission (p0.001). The AUC of CTP, MELD, and MELD-Na in predicting three-months mortality were 0.828, 0.845, and 0.862 (p0.05), and the AUC of each score system for death within one year were 0.792, 0.800, and 0.831, respectively (p0.05). The AUC of MELD-Na in predicting short term death were the highest, although it was not statistically significant. Multivariate analysis showed that only MELD-Na was significantly related to three-month mortality (p=0.012).
CONCLUSIONS: MELD-Na is more appropriate in predicting short term mortality, but larger scale studies are needed to confirm the superiority of MELD-Na to MELD and CTP in patients with liver cirrhosis.

Entities:  

Mesh:

Year:  2007        PMID: 17928752

Source DB:  PubMed          Journal:  Korean J Gastroenterol        ISSN: 1598-9992


  6 in total

1.  Comparison of four models for end-stage liver disease in evaluating the prognosis of cirrhosis.

Authors:  Ming Jiang; Fei Liu; Wu-Jun Xiong; Lan Zhong; Xi-Mei Chen
Journal:  World J Gastroenterol       Date:  2008-11-14       Impact factor: 5.742

2.  Serum potassium levels and prognosis in HBV-associated decompensated cirrhosis.

Authors:  JianJiang Huang; Ming Cai; Xia He
Journal:  J Clin Lab Anal       Date:  2021-05-05       Impact factor: 2.352

3.  Comparison of the Child-Turcotte-Pugh classification and the model for end-stage liver disease score as predictors of the severity of the systemic inflammatory response in patients undergoing living-donor liver transplantation.

Authors:  Sang-Hyun Hong; Jeong-Eun Kim; Mi-La Cho; Yu-Jung Heo; Jong-Ho Choi; Jung-Hyun Choi; Jaemin Lee
Journal:  J Korean Med Sci       Date:  2011-10-01       Impact factor: 2.153

4.  The model for end-stage liver disease score-based system predicts short term mortality better than the current Child-Turcotte-Pugh score-based allocation system during waiting for deceased liver transplantation.

Authors:  Geun Hong; Kwang-Woong Lee; Sukwon Suh; Tae Yoo; Hyeyoung Kim; Min-Su Park; Youngrok Choi; Nam-Joon Yi; Kyung-Suk Suh
Journal:  J Korean Med Sci       Date:  2013-07-31       Impact factor: 2.153

Review 5.  Child-Pugh Versus MELD Score for the Assessment of Prognosis in Liver Cirrhosis: A Systematic Review and Meta-Analysis of Observational Studies.

Authors:  Ying Peng; Xingshun Qi; Xiaozhong Guo
Journal:  Medicine (Baltimore)       Date:  2016-02       Impact factor: 1.889

6.  Mid-infrared spectroscopy of serum, a promising non-invasive method to assess prognosis in patients with ascites and cirrhosis.

Authors:  Maëna Le Corvec; Caroline Jezequel; Valérie Monbet; Nadia Fatih; Frédéric Charpentier; Hugues Tariel; Catherine Boussard-Plédel; Bruno Bureau; Olivier Loréal; Olivier Sire; Edouard Bardou-Jacquet
Journal:  PLoS One       Date:  2017-10-11       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.